Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat effect on Midazolam PK in healthy subjects
NCT03187015Phase 1Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in breast cancer, sponsored by Syndax Pharmaceuticals. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration at 24 hours, Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity at 24 hours and 1 more. Started May 2017; status: completed.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03187015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187015.